Pace Diagnostics2

Revolutionary point-of-care, affordable early detection Lung cancer and Tuberculosis diagnostics

Print
Claim My Business
Form C
View on Wefunder
Security Type
CAFES
Categories
Technology, Retail, Financial Services, Healthcare & Medical, Community & Lifestyle, Education
Min Investment
$200
Location
Monrovia, CA
Expected Close Date
April 30, 2023
Target Raise
$50.00K-$1.07M
No. Investors
136
Security Price
$1
Deal Notes

Raised $2.5 million in seed investment; Won > $6 million in grants from US DoD, NIH, and NSF Huge markets and financial opportunities: 3.1 billion USD tuberculosis & 20 billion USD lung cancer diagnostics in 2022 Our products - low cost, accurate, non-invasive, non-lab dependent lung cancer & tuberculosis tests Our CE Mark is targeted by Q1 2022, allowing product distribution in EU countries; clear path to FDA clinical trials We have a portfolio of proprietary material, filed patents and licensed IPs Each year: 10 million new TB infections & 2 million deaths; 2.1 million new Lung Cancer cases & 2 million new deaths Our TB test is specifically developed to meet all WHO requirements for performance, cost and use British Biocell International (BBI) is our manufacturing partner

Website
pacediagnostics.com
Number of Employees
8
Cash
$118,080
Revenue
$0
Short Term Debt
$109,506
Cost of Goods
$0
Long Term Debt
$969,184
Net Income
$-338,096

Company Description

Raised $2.5 million in seed investment; Won > $6 million in grants from US DoD, NIH, and NSF
Huge markets and financial opportunities: 3.1 billion USD tuberculosis & 20 billion USD lung cancer diagnostics in 2022
Our products - low cost, accurate, non-invasive, non-lab dependent lung cancer & tuberculosis tests
Our CE Mark is targeted for 2022, allowing product distribution in EU countries; clear path to FDA clinical trials
We have a portfolio of proprietary material, filed patents and licensed IPs
Each year: 10 million new TB infections & 2 million deaths; 2.1 million new Lung Cancer cases & 2 million new deaths
Our TB test is specifically developed to meet all WHO requirements for performance, cost and use
British Biocell International (BBI) is our manufacturing partner

Perks

500 - Pace Diagnostics T-Shirt

1000 - Pace Diagnostics T-Shirt and Mystery specialty gift box

5000 - All Above + Zoom call with the founders + virtual lab tour

20000 - All Above + Lunch at prestigious faculty club + lab tour with the founders next time you're in town

Management Team / Advisory Board Bios

Hiep Hoa T Nguyen President & CEO Lorne Mattnew COO Sunjay Jayachandran Co founder

Deal Notes

Raised $2.5 million in seed investment; Won > $6 million in grants from US DoD, NIH, and NSF Huge markets and financial opportunities: 3.1 billion USD tuberculosis & 20 billion USD lung cancer diagnostics in 2022 Our products - low cost, accurate, non-invasive, non-lab dependent lung cancer & tuberculosis tests Our CE Mark is targeted by Q1 2022, allowing product distribution in EU countries; clear path to FDA clinical trials We have a portfolio of proprietary material, filed patents and licensed IPs Each year: 10 million new TB infections & 2 million deaths; 2.1 million new Lung Cancer cases & 2 million new deaths Our TB test is specifically developed to meet all WHO requirements for performance, cost and use British Biocell International (BBI) is our manufacturing partner

Amount Raised : $187,385
Reveal the Score by Voting
＿
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
ⓘ
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
ⓘ
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
ⓘ
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
ⓘ
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

A CAFES (Contract and Future Equity Stake) can convert into different types of equity upon a Triggering Event, such as: common or preferred stock for a corporation, limited partnership interest for a limited partnership and membership interest for a limited liability company. At the time of the Triggering Event, the specific rights and limitations associated with the equity stake being issued to the investors will be determined and disclosed by the Entrepreneur.

Research Reports

No reports have been submitted

Become a Reporter
Read Our Research Disclaimer

0 Comments

Post Comment